We remind investors that in 2009, Incyte and Lilly had entered into an exclusive worldwide license and collaboration agreement to develop and commercialize baricitinib and certain follow-on compounds, for the treatment of patients with inflammatory and …
(Visited 1 times, 1 visits today)
Comments
Comments are disabled for this post.